Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUTENSIN vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of Rauwolfia serpentina alkaloids (e.g., reserpine) that deplete catecholamines and serotonin from peripheral sympathetic nerve endings and brain, reducing total peripheral resistance and cardiac output.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension,Mild essential hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
1-2 tablets (each containing Rauwolfia serpentina 50 mg and flumethiazide 0.5 mg) orally once daily.
250 mg orally twice daily
The terminal elimination half-life of rauwolfia alkaloids is approximately 50-100 hours, with a mean of about 72 hours. This long half-life supports once-daily dosing and leads to slow accumulation and sustained antihypertensive effect.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Extensively metabolized in the liver via deacetylation and hydrolysis; reserpine is metabolized by CYP3A4 and carboxyl esterase.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Rautensin (rauwolfia alkaloids) is primarily excreted via hepatic metabolism and biliary-fecal elimination, with less than 1% excreted unchanged in urine. Renal excretion accounts for approximately 10% of metabolites, while biliary/fecal elimination accounts for approximately 90%.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Protein binding is approximately 50-60%, primarily to albumin and alpha-1-acid glycoprotein.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution (Vd) is approximately 1.6 L/kg, indicating extensive tissue distribution and accumulation in adipose tissue. This high Vd contributes to the long half-life.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral bioavailability is variable, estimated at approximately 50-60% due to extensive first-pass hepatic metabolism. Bioavailability is route-specific: oral only, as no parenteral formulations are clinically available.
70-90% (oral); 100% (IV).
GFR 30-59 m L/min: reduce dose by 50%; GFR <30 m L/min: contraindicated due to thiazide component.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended for use in children; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at lowest dose (0.5 tablet once daily); monitor for hypotension and electrolyte imbalance.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause mental depression, especially in patients with history of depression,Use caution in patients with gastric ulcers (may increase gastric acid secretion),Avoid in patients undergoing electroconvulsive therapy (ECT),May cause hypotension and bradycardia,Discontinue 2 weeks before elective surgery
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to any component,Active peptic ulcer (may exacerbate),History of electroconvulsive therapy,Parkinsonism,Depression (especially with suicidal tendencies)
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, tomatoes) unless advised by a doctor. Thiazide diuretics can cause potassium depletion, but reserpine may blunt this effect. Limit alcohol consumption. Maintain adequate fluid intake to prevent dehydration.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Rautensin contains reserpine and other rauwolfia alkaloids. Reserpine crosses the placenta. First trimester: limited data, but animal studies suggest potential for fetal harm (neural tube defects, cardiovascular anomalies) at high doses. Second and third trimesters: risk of neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to catecholamine depletion. Avoid use during pregnancy, especially after 20 weeks gestation.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Reserpine is excreted into breast milk. M/P ratio: approximately 1:1. Potential for serious adverse effects in the nursing infant, including respiratory depression, bradycardia, and gastrointestinal disturbances. Breastfeeding is not recommended during maternal therapy with Rautensin.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Pregnancy-induced physiologic changes (increased plasma volume, renal clearance) may lower reserpine serum levels. However, due to teratogenic and neonatal risks, Rautensin is contraindicated in pregnancy. No dosing adjustments are recommended because use is not advised. Consider alternative antihypertensives with established safety profiles.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Rautensin is a combination of Rauwolfia alkaloids (e.g., reserpine) and a thiazide diuretic (e.g., bendroflumethiazide). It is rarely used today due to better-tolerated alternatives. Monitor for orthostatic hypotension, especially in elderly. Check serum potassium and uric acid regularly due to thiazide component. Reserpine can cause depression and nasal congestion; discontinue if depressive symptoms emerge. Avoid in patients with history of depression or peptic ulcer disease.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not stop abruptly as it may cause rapid rise in blood pressure.,Rise slowly from sitting or lying down to prevent dizziness.,This medication can cause drowsiness; avoid driving until you know how it affects you.,Report any signs of depression, mood changes, or unusual tiredness.,Avoid alcohol and other sedatives; they can increase dizziness and drowsiness.,If you experience nasal congestion, it may be due to the medication; consult your doctor.,Regular blood tests are needed to monitor potassium and uric acid levels.,Use effective contraception if of childbearing age; discuss with your doctor.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUTENSIN vs ALDOCLOR-250, answered by our medical review team.
RAUTENSIN is a Antihypertensive that works by Combination of Rauwolfia serpentina alkaloids (e.g., reserpine) that deplete catecholamines and serotonin from peripheral sympathetic nerve endings and brain, reducing total peripheral resistance and cardiac output.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUTENSIN and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUTENSIN is: 1-2 tablets (each containing Rauwolfia serpentina 50 mg and flumethiazide 0.5 mg) orally once daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUTENSIN and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUTENSIN is classified as Category C. Rautensin contains reserpine and other rauwolfia alkaloids. Reserpine crosses the placenta. First trimester: limited data, but animal studies suggest potential for fetal harm (neur. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.